BRIEF-FDA Calls On Infant Formula Industry To Strengthen Supplier Oversight Amid Contamination Risks

July 13 (Reuters) - FDA:

  • FDA CALLS ON INFANT FORMULA INDUSTRY TO BETTER SAFEGUARD AGAINST CONTAMINANTS INTRODUCED THROUGH THEIR SUPPLY CHAIN

  • FDA: EXPECTS MANUFACTURERS TO EXERCISE SUBSTANTIVE OVERSIGHT OF THEIR SUPPLIERS AND WHETHER RISKS ARE EFFECTIVELY CONTROLLED

  • FDA: RECOMMENDS INFANT FORMULA MANUFACTURERS & SUPPLY CHAIN PARTNERS MONITOR APPLICABLE RECALL NOTIFICATIONS, OUTBREAK INVESTIGATIONS, IMPORT ALERTS

  • FDA: INVESTIGATING ROOT CAUSES OF 2025 & 2026 INFANT BOTULISM OUTBREAKS ASSOCIATED WITH POWDERED INFANT FORMULA; HAS COMPLETED INITIAL SURVEILLANCE


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.